ASIANET: Daily Summary on Monday, July 02, 2001


Jul 3--PRNewswire/AsiaNet


HEPATITIS B DEAL...

CAMBRIDGE: Novirio and Sumitomo Pharmaceuticals have struck a deal for the Hepatitis B treatment, LdT, that will convey commercial rights for key Asian markets to Sumitomo, and evenly apportion development costs and sales royalties.

TELCO BROADBAND DEAL...

FREMONT: Global broadband infrastructure provider, ARESCOM Inc, announced today that its services had been adopted by South American telecommunication giant, Telefonica.

ECONOMIC DEVELOPMENT BOARD AWARD...

SINGAPORE: Singapore's Economic Development Board has accorded BAX Global Inc, the global transportation and logistic provider, its Business Headquarters Award, given to companies that invest substantially in Singapore by establishing regional or global headquarters there.

DISK PROJECTIONS REVISED...

SAN JOSE: Disk drive media producer, Komag Inc, today said overall weak economic conditions would cause its shipment volumes to drop from 14 million to 11 million disks, while its global debt restructuring plan would be revised.

COAL OWNERSHIP COMPLETE...

TORONTO: Sherrit Coal Partnership today claimed full ownership of Luscar Coal Income Fund, holding all of its outstanding units and debentures.

(AsiaNet is a consortium of leading news agencies distributing unedited, translated press releases for worldwide clients. Contact: www.asianet.com.au for full-text versions).




















ข่าวHepatitis B+Telefonicaวันนี้

ASIANET: Daily Summary on Monday, July 02, 2001

HEPATITIS B DEAL... CAMBRIDGE: Novirio and Sumitomo Pharmaceuticals have struck a deal for the Hepatitis B treatment, LdT, that will convey commercial rights for key Asian markets to Sumitomo, and evenly apportion development costs and sales royalties. TELCO BROADBAND DEAL... FREMONT: Global broadband infrastructure provider, ARESCOM Inc, announced today that its services had been adopted by South American telecommunication giant, Telefonica. ECONOMIC DEVELOPMENT BOARD AWARD... SINGAPORE:

มะเร็งตับ ( Hepatocellular carcinoma ) เป... การรักษามะเร็งตับด้วยการให้เคมีบำบัดผ่านทางหลอดเลือด — มะเร็งตับ ( Hepatocellular carcinoma ) เป็นเนื้องอกชนิดหนึ่งที่พบมากในประเทศไทย ส่วนใหญ่พบในเพศชาย...

Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer

Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product...

Janssen to Discontinue Hepatitis C Development Program

- Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational...

Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)

- Includes several late breaking and oral presentations from across R&D pipeline - Highlights potential of R&D pipeline to deliver several new...

BioNet to enter Hepatitis B vaccine production

Could become the only company in the world to produce both recombinant acellular pertussis and recombinant Hepatitis B vaccines BioNet-Asia Co., Ltd., the only privately-owned biotech company in Thailand focusing on the development, manufacturing and...

World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic

- Shocking Lack of Global Statistics Prompts Creation of First Global Resource on Hepatitis: The Hepatitis Atlas The World Hepatitis Alliance, a newly formed Non-Governmental...

A Treatment-Free Life is Possible for Millions of Hepatitis B Patients, PEGASYS(R) Study Reveals

Prior Treatment with 'Maintenance Therapy' Medications No Barrier to Achieving Sustained Response with PEGASYS Hope of a treatment-free life for millions of hepatitis B patients currently having to take...

Second New England Journal of Medicine Paper Establishes PEGASYS(R) as a First-Line Therapy in Chronic Hepatitis B

PEGASYS Offers Greater Benefit Versus Current Standard of Care Results published today in the prestigious New England Journal of Medicine have led the study authors to recommend PEGASYS...

PEGASYS Doubles the Efficacy in Difficult-to-Treat Hepatitis B Virus Versus Conventional Interferon

Study results presented today at the 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney Australia demonstrate that PEGASYS, a new generation hepatitis C therapy, more than...